Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update
出版年份 2022 全文链接
标题
Clinical Pharmacogenetics Implementation Consortium Guideline for
CYP2C19
Genotype and Clopidogrel Therapy: 2022 Update
作者
关键词
-
出版物
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2022-01-16
DOI
10.1002/cpt.2526
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Clopidogrel Versus Ticagrelor or Prasugrel After Primary Percutaneous Coronary Intervention According to CYP2C19 Genotype
- (2021) Daniel M.F. Claassens et al. Circulation-Cardiovascular Interventions
- Effect of CYP2C19 Genotype on Ischemic Outcomes During Oral P2Y12 Inhibitor Therapy
- (2021) Naveen L. Pereira et al. JACC-Cardiovascular Interventions
- Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis
- (2021) Mattia Galli et al. LANCET
- Ticagrelor versus Clopidogrel in CYP2C19 Loss-of-Function Carriers with Stroke or TIA
- (2021) Yongjun Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Derivation, Validation, and Prognostic Utility of a Prediction Rule for Nonresponse to Clopidogrel
- (2020) Dominick J. Angiolillo et al. JACC-Cardiovascular Interventions
- Genome‐wide association study of platelet reactivity and cardiovascular response in patients treated with clopidogrel: a study by the International Clopidogrel Pharmacogenomics Consortium (ICPC)
- (2020) Shefali Setia Verma et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial
- (2020) Marieke Gimbel et al. LANCET
- PharmVar GeneFocus: CYP2C19
- (2020) Mariana R. Botton et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype‐Guided Antiplatelet Therapy After Percutaneous Coronary Intervention
- (2020) Craig R. Lee et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
- (2020) Jean-Philippe Collet et al. EUROPEAN HEART JOURNAL
- Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention
- (2020) Naveen L. Pereira et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Use of Prasugrel and Ticagrelor in Stable Ischemic Heart Disease After Percutaneous Coronary Intervention, 2009–2016
- (2019) Elias J. Dayoub et al. Circulation-Cardiovascular Interventions
- Structural variation at the CYP2C locus: Characterization of deletion and duplication alleles
- (2019) Mariana R. Botton et al. HUMAN MUTATION
- A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI
- (2019) Daniel M.F. Claassens et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacogenomic Polygenic Response Score Predicts Ischemic Events and Cardiovascular Mortality in Clopidogrel-Treated Patients
- (2019) Joshua P Lewis et al. European Heart Journal-Cardiovascular Pharmacotherapy
- Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention
- (2018) Larisa H. Cavallari et al. JACC-Cardiovascular Interventions
- Recommendations for Clinical CYP2C19 Genotyping Allele Selection
- (2018) Victoria M. Pratt et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Trends in Platelet Adenosine Diphosphate P2Y12 Receptor Inhibitor Use and Adherence Among Antiplatelet-Naive Patients After Percutaneous Coronary Intervention, 2008-2016
- (2018) Elias J. Dayoub et al. JAMA Internal Medicine
- CYP2C19 genotype and adverse cardiovascular outcomes after stent implantation in clopidogrel-treated Asian populations: A systematic review and meta-analysis
- (2017) Ziwei Xi et al. PLATELETS
- Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic AttackClinical Perspective
- (2016) Yuesong Pan et al. CIRCULATION
- Exome sequencing of extreme clopidogrel response phenotypes identifiesB4GALT2as a determinant of on-treatment platelet reactivity
- (2016) SA Scott et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel
- (2016) Willibald Hochholzer et al. THROMBOSIS AND HAEMOSTASIS
- Contemporary Use of Ticagrelor in Interventional Practice (from Blue Cross Blue Shield of Michigan Cardiovascular Consortium)
- (2015) Amrita M. Karve et al. AMERICAN JOURNAL OF CARDIOLOGY
- Effect of high-dose clopidogrel according to CYP2C19*2 genotype in patients undergoing percutaneous coronary intervention– a systematic review and meta-analysis
- (2015) Lanning Zhang et al. THROMBOSIS RESEARCH
- Increased Uptake of Guideline-Recommended Oral Antiplatelet Therapy: Insights from the Canadian Acute Coronary Syndrome Reflective
- (2014) Sumeet Gandhi et al. CANADIAN JOURNAL OF CARDIOLOGY
- 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
- (2014) Ezra A. Amsterdam et al. CIRCULATION
- CYP2C19 Genotype Has a Greater Effect on Adverse Cardiovascular Outcomes Following Percutaneous Coronary Intervention and in Asian Populations Treated With Clopidogrel: A Meta-Analysis
- (2014) M. J. Sorich et al. Circulation-Cardiovascular Genetics
- Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers
- (2014) Richard B. Horenstein et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update
- (2013) S A Scott et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- TheCYP2C19*17 variant is not independently associated with clopidogrel response
- (2013) J. P. Lewis et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
- (2011) et al. CIRCULATION
- Dosing Clopidogrel Based on CYP2C19 Genotype and the Effect on Platelet Reactivity in Patients With Stable Cardiovascular Disease
- (2011) Jessica L. Mega et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement
- (2010) Dirk Sibbing et al. CIRCULATION
- Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI
- (2010) Jessica L. Mega et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy
- (2010) D. SIBBING et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial
- (2010) Lars Wallentin et al. LANCET
- Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel
- (2009) Jessica L. Mega et al. CIRCULATION
- Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to Its Pharmacologically Active Metabolite
- (2009) M. Kazui et al. DRUG METABOLISM AND DISPOSITION
- Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy
- (2009) Alan R. Shuldiner JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
- (2009) Lars Wallentin et al. NEW ENGLAND JOURNAL OF MEDICINE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started